New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
07:03 EDTENDP, BDSIBioDelivery Sciences announces Buprenorphine study to be locked by Endo Health
The database for the BEMA Buprenorphine Phase 3 clinical study in opioid naive patients with chronic pain is expected to be locked shortly by BDSI's partner, Endo Pharmaceuticals. This event is expected to trigger a $10M milestone payment from Endo per the licensing and development agreement signed in January 2012. In addition, based on recruitment rates in a second Phase 3 clinical study of BEMA Buprenorphine in an opioid experienced patient group, the database for this trial is anticipated to be locked by mid-2014, with results following shortly thereafter.
News For BDSI;ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 8, 2016
10:00 EDTBDSIOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:35 EDTBDSIBioDelivery Sciences initiated with an Overweight at Piper Jaffray
Subscribe for More Information
February 5, 2016
13:35 EDTENDPEndo rallies amid talk of conference cancellation
Shares of Endo International are rallying 2% amid talk the company cancelled out of Leerink's conference next week. Endo has no events listed on its website and Bloomberg just reported that according to sources, the company cancelled its appearance at the conference. Shares of Endo are up $1.25 to $55.40 in afternoon trading.
February 1, 2016
10:25 EDTENDPWilliaOptions with increasing implied volatility: WMB ENDP RAD
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use